Spending in medical journals during the first half of 2018 may not have reached the levels seen in the recent past. At the same time, pharma companies don’t appear to be trimming their investments.
An estimated 10.7 million teens are vaping or thinking about it.
Teva’s Ajovy becomes the second approved CGRP migraine therapy, following Amgen’s Aimovig.
How does one create an effective market access program in the current healthcare environment? Experts share seven tips for success.
Amarin’s Vascepa trial is set to read out results by the end of September.
As more medications are approved, pharma companies are being pushed farther afield into a land of bizarre — but hopefully still memorable and vaguely meaningful — drug names.
The companies plan to make the most of favorable market access conditions for the at-home colon cancer screening test.
Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.
The two diabetes rivals air competing TV spots as they compete for GLP-1 supremacy.
Matt McNally, CEO of Outcome Health, shares his thoughts on post-controversy Outcome Health and the overall state of the point-of-care union.
Please login or register first to view this content.
